Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia

In recent decades, survival rates for childhood acute lymphoblastic leukemia have improved remarkably, as demonstrated by risk-stratified, prospective multicenter studies. Treatment protocols have evolved and become better matched to both prognostic factors and treatment responses. Recently, new mol...

Full description

Bibliographic Details
Main Author: Hyery Kim
Format: Article
Language:English
Published: The Korean Society of Pediatric Hematology-Oncology 2019-04-01
Series:Clinical Pediatric Hematology-Oncology
Subjects:
Online Access:https://doi.org/10.15264/cpho.2019.26.1.12
id doaj-8f6b39f2277e40449f721124a22232c2
record_format Article
spelling doaj-8f6b39f2277e40449f721124a22232c22020-11-25T03:25:28ZengThe Korean Society of Pediatric Hematology-OncologyClinical Pediatric Hematology-Oncology2233-52502019-04-01261122610.15264/cpho.2019.26.1.12cpho.2019.26.1.12Advances in the Treatment of Childhood Acute Lymphoblastic LeukemiaHyery Kim0Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaIn recent decades, survival rates for childhood acute lymphoblastic leukemia have improved remarkably, as demonstrated by risk-stratified, prospective multicenter studies. Treatment protocols have evolved and become better matched to both prognostic factors and treatment responses. Recently, new molecular prognostic factors have been discovered in leukemia genomic studies. New tumor subtypes with independent gene expression profiles have also been characterized. Furthermore, therapies targeted to specific candidate mutations are being identified to broaden therapeutic options for patients with poor prognoses. Many new drugs are in clinical trials and immunotherapy is attracting significant interest for the treatment of recurrent or refractory disease in childhood acute lymphoblastic leukemia.https://doi.org/10.15264/cpho.2019.26.1.12childhoodprecursor cell lymphoblastic leukemiaprognosissurvival
collection DOAJ
language English
format Article
sources DOAJ
author Hyery Kim
spellingShingle Hyery Kim
Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia
Clinical Pediatric Hematology-Oncology
childhood
precursor cell lymphoblastic leukemia
prognosis
survival
author_facet Hyery Kim
author_sort Hyery Kim
title Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia
title_short Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia
title_full Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia
title_fullStr Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia
title_full_unstemmed Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia
title_sort advances in the treatment of childhood acute lymphoblastic leukemia
publisher The Korean Society of Pediatric Hematology-Oncology
series Clinical Pediatric Hematology-Oncology
issn 2233-5250
publishDate 2019-04-01
description In recent decades, survival rates for childhood acute lymphoblastic leukemia have improved remarkably, as demonstrated by risk-stratified, prospective multicenter studies. Treatment protocols have evolved and become better matched to both prognostic factors and treatment responses. Recently, new molecular prognostic factors have been discovered in leukemia genomic studies. New tumor subtypes with independent gene expression profiles have also been characterized. Furthermore, therapies targeted to specific candidate mutations are being identified to broaden therapeutic options for patients with poor prognoses. Many new drugs are in clinical trials and immunotherapy is attracting significant interest for the treatment of recurrent or refractory disease in childhood acute lymphoblastic leukemia.
topic childhood
precursor cell lymphoblastic leukemia
prognosis
survival
url https://doi.org/10.15264/cpho.2019.26.1.12
work_keys_str_mv AT hyerykim advancesinthetreatmentofchildhoodacutelymphoblasticleukemia
_version_ 1724596877327859712